FAB'ENTECH
Founded in 2009 in Lyon, France and located and member of LyonBiopôle cluster, Fab’entech is a biopharmaceutical company which develops and commercializes a range of innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)₂] in the field of emerging infectious diseases, as well as for certain drug intoxications.
FAB'ENTECH
Industry:
Health Care Medical Public Safety
Founded:
2009-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.fabentech.com
Total Employee:
11+
Status:
Active
Contact:
+33 (0)4 37 70 67
Email Addresses:
[email protected]
Total Funding:
13.5 M EUR
Technology used in webpage:
SPF Euro IPv6 1and1
Similar Organizations
Accurx
Accurx is on a mission to make patients healthier and healthcare staff happier, through seamless communication.
BetterNight
BetterNight is providing telehealth-based sleep solutions.
GGD Amsterdam
GGD Amsterdam is a public health department.
Healios
The UK’s leading digital healthcare company .
Medigo
Medigo enables global access to quality healthcare.
Push Doctor
Push Doctor is creating the future of healthcare.
Spire Healthcare
Spire Healthcare is a hospital group providing inpatient and outpatient care, diagnostics, and primary care.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Series C - Fab'entech
Elaia
Elaia investment in Series C - Fab'entech
Auriga Partners
Auriga Partners investment in Series A - Fab'entech
Sigma Gestion
Sigma Gestion investment in Series A - Fab'entech
Rhone-Alpes Creation
Rhone-Alpes Creation investment in Series A - Fab'entech
Official Site Inspections
http://www.fabentech.com
- Host name: 217-160-0-235.elastic-ssl.ui-r.com
- IP address: 217.160.0.235
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Fab'entech"
Accueil - Fabentech
Fabentech est spécialisée dans le développement et la production de traitements d’urgence contre le bioterrorisme et les maladies infectieuses émergentes.See details»
Home - Fabentech
Fabentech specialises in the development and production of emergency treatments to fight the highest-priority biological threats to public health.See details»
About us - Fabentech
Founded in 2009, Fabentech specialises in the development and production of polyclonal antibody treatments for fighting high-priority biological agents which could threaten public health.See details»
Fab'entech - Crunchbase Company Profile & Funding
Founded in 2009 in Lyon, France and located and member of LyonBiopôle cluster, Fab’entech is a biopharmaceutical company which develops and …See details»
Fabentech - LinkedIn
Fabentech remains committed to reinforcing resilience and ensuring rapid responses to biological threats leveraging on its broad-spectrum technology.See details»
Fab’entech - VentureRadar
Founded in 2009, FABENTECH is a French biotech company specialized in the development and production of polyclonal antibodies intended for treating emerging infectious diseases, and for …See details»
FABENTECH Company Profile | LYON, AUVERGNE RHONE ALPES, …
Find company research, competitor information, contact details & financial data for FABENTECH of LYON, AUVERGNE RHONE ALPES. Get the latest business insights from Dun & Bradstreet.See details»
fabentech
Fab’entech is a French biopharmaceutical SME developing immunotherapies to address situations of medical emergency. Based on a fully-derisked technology in-licensed from Sanofi …See details»
Fab'entech Management Team | Org Chart - RocketReach
Fab'entech employs 45 employees. The Fab'entech management team includes Sébastien IVA (Chief Executive Officer), Bertrand LEPINE (Board member and Founder), and Cécile …See details»
FAB'ENTECH - Lyonbiopôle
Member of Lyonbiopole Fab’entech is a privately owned biopharmaceutical SME developing immunotherapies to address situations of emergency. Based on its horse F (ab’)2 platform, a …See details»
À propos - Fabentech
Fabentech a plus de 14 années d’expérience dans le développement et la production de solutions de soins d'urgence et de contre-mesures médicales.See details»
FABENTECH Company Profile | ST PRIEST, AUVERGNE ... - Dun
Find company research, competitor information, contact details & financial data for FABENTECH of SAINT-PRIEST, AUVERGNE RHONE ALPES. Get the latest business insights from Dun & …See details»
☑️Fabentech — Consulting Organization from ... - DevelopmentAid
Fabentech — Consulting Organization from France with 11-50 employees, has experience with European Commission Directorate-General for International Partnerships (EuropeAid HQ), …See details»
Fabentech Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Fabentech. Use the PitchBook Platform to explore the full profile.See details»
Fab'entech - Overview, News & Similar companies | ZoomInfo.com
Dec 12, 2021 View Fab'entech (www.fabentech.com) location in Auvergne-Rhone-Alpes, France , revenue, industry and description. Find related and similar companies as well as employees …See details»
Mission - Fabentech
Fabentech collaborates closely with governments and healthcare organisations, providing timely and effective medical countermeasures against highly pathogenic agents.See details»
Fabentech - Company Profile - Tracxn
Feb 28, 2025 Fabentech - Developing polyclonal antibodies to treat infectious diseases such as avian influenza, ebola etc.. Raised a total funding of $6.84M over 5 rounds from 6 investors.See details»
Fabentech SAS: Drug pipelines, Patents, Clinical trials - Synapse
Explore Fabentech SAS with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, and 2 literature, Disease Domain:Infectious Diseases, Technology Platform:Polyclonal …See details»
Pipeline - Fabentech
Fabentech’s diverse portfolio features life-saving solutions designed to neutralise the most critical viruses and biological toxins, providing a crucial defence against potentially deadly threats.See details»
Technology - Fabentech
Fabentech’s cutting-edge technology produces highly purified polyclonal F(ab')2 that recognise and bind to the pathogen, and stop disease progression.See details»